查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1946344

结膜炎治疗市场－全球产业规模、份额、趋势、机会及预测（依疾病类型、製剂类型、地区及竞争格局划分，2021-2031年）

Conjunctivitis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Formulation Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球结膜炎治疗市场预计将从 2025 年的 58.7 亿美元成长到 2031 年的 79.4 亿美元，复合年增长率为 5.16%。

该市场涵盖多种药物製剂，包括抗病毒药物、抗生素、抗组织胺药物和肥大细胞稳定剂，旨在控制感染疾病和减轻结膜发炎。病毒性和过敏性结膜炎在全球发病率的上升是推动市场成长的主要因素，而过敏原暴露增加和环境污染往往会加剧病情。此外，人们对眼部健康的日益重视以及隐形眼镜的广泛使用也是推动市场成长的因素。根据小儿科感染疾病学会2024年报告，每年约有八分之一的儿童患有感染疾病结膜炎，这为该市场提供了巨大的需求基础。

市场概览
预测期 2027-2031
市场规模：2025年 58.7亿美元
市场规模：2031年 79.4亿美元
复合年增长率：2026-2031年 5.16%
成长最快的细分市场 过敏性结膜炎
最大的市场 北美洲

儘管成长指标积极，但由于重磅药物专利到期以及非专利药竞争加剧，市场仍面临许多挑战。这些低成本学名药的进入给现有製药公司的价格和利润率带来了巨大的下行压力，可能抑制其对新药研发的投资。因此，这种竞争环境会削弱品牌药的盈利，并使市场充斥着同质化的治疗方案，从而对市场扩张构成挑战。

市场驱动因素

全球感染疾病和过敏性结膜炎盛行率的不断上升是推动治疗市场成长的主要因素，从而对各种治疗方法产生了稳定的需求。频繁的季节性流行以及成年人群中慢性过敏性疾病负担的加重进一步加剧了这一趋势。例如，根据《印度斯坦时报》报道，2025年6月，孟买医院由季节性病毒引起的结膜炎病例激增20-30%，凸显了感染潮带来的快速传播和突发性需求激增。此外，非传染性疾病也在扩大市场范围。美国国立卫生研究院2025年7月引用的一项研究表明，英国约有八分之一的成年人患有过敏性鼻结膜炎，这意味着庞大的患者群体需要在儿童以外的长期管理。

同时，大量新型疗法的核准和上市正在重塑市场格局，为患者提供更先进、更便利的治疗选择。製药公司积极响应这项需求，推出现有药物药物的创新配方和经济实惠的学名药。在这一竞争格局中，Glenmark Pharmaceuticals公司于2025年3月获得FDA核准的0.2%盐酸奥洛他定滴眼液（USP）上市（根据Barchart数据），成为一项关键进展，扩大了有效治疗眼痒的途径。持续涌现的核准疗法不仅有助于改善患者的用药途径，还能根据结膜炎的严重程度提供个人化解决方案，进而提升市场价值。

市场挑战

重磅药物专利到期以及随之而来的非专利竞争，对全球结膜炎治疗药物市场的财务扩张构成了重大障碍。当专利配方失去独占权后，市场上充斥着大量价格较低的学名药，导致价格大幅下降。这种转变使成熟的治疗方法商品化，即使处方量保持稳定甚至成长，也会导致製药开发商的收入急剧下降。由于专利到期药物导致的利润率降低，限制了可用于研发再投资的资金，延缓了能够推动未来市场价值成长的创新高价值治疗方案的推出。

处方量与产生收入之间的脱节鲜明地体现了这种价值侵蚀。根据美国可及药品协会（Association for Accessible Medicines）预测，到2025年，学名药将占美国处方笺的90%，但仅占药品总支出的12%。这项数据表明，儘管患者用药量依然很高，但由于低成本学名药占据市场主导地位，市场所获得的货币价值却不成比例地低。这种扭曲的财务状况抑制了整体市场成长，因为高收入的品牌药销售被低利润的仿製药销售所取代，最终导致相关人员不愿在眼科药物输送技术领域投入高成本的研发。

市场趋势

远距眼科的整合正在革新病患分诊流程，尤其是在传染性病毒疾病方面。透过远端评估，临床医生无需进行身体接触即可有效区分过敏性和感染性病因，从而显着降低拥挤的临床环境中的感染风险。这种方法已被广泛采用，成为眼表疾病的主要筛检工具。根据2025年1月发表在《医师週刊》（Physicians Weekly）上的报导《远距眼科作为急性眼疾的有效分诊工具》，一项对6000多名患者的回顾性研究发现，所有远端医疗就诊中有15.5%是针对结膜疾病的，这凸结了远距会诊在急性病情就诊中的重要性。

同时，奈米技术在眼科治疗的应用正在解决传统眼药水生物利用度低这一重大难题。新型奈米载体，例如奈米混悬液，正在被开发用于提高皮质类固醇的溶解度和组织渗透性，这对于治疗严重的发炎性结膜炎至关重要。与传统製剂相比，这些先进的递送系统能够确保快速起效并维持疗效。例如，根据2025年2月《现代验光》杂誌上题为“2024年回顾：FDA核准和产品上市”的报导，一种新型水性悬浮液——0.05%Clobetasol Propionate索悬浮液——在四天内使80%的患者疼痛完全缓解，凸显了基于奈米技术的製剂在治疗眼部炎症方面的卓越疗效。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球结膜炎治疗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依疾病类型（过敏性结膜炎、细菌性结膜炎、病毒性结膜炎）
    • 依剂型类型（软膏、眼药水、口服药物）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美结膜炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲结膜炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区结膜炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲结膜炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲结膜炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球结膜炎治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Novartis AG
  • Bausch & Lomb Inc
  • Allergan UnLtd Co
  • Nicox SA
  • Alembic Pharmaceuticals Ltd
  • Sanofi SA
  • Pfizer Inc
  • Sirion Therapeutics Inc
  • SANTEN PHARMACEUTICAL CO., LTD.
  • Auven Therapeutics Management LLLP

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19544

The Global Conjunctivitis Treatment Market is projected to expand from a valuation of USD 5.87 Billion in 2025 to USD 7.94 Billion by 2031, reflecting a CAGR of 5.16%. This market sector encompasses a broad spectrum of pharmaceutical formulations, such as antivirals, antibiotics, antihistamines, and mast cell stabilizers, all aimed at managing infection and reducing conjunctival inflammation. Market growth is fundamentally underpinned by the escalating global incidence of viral and allergic conjunctivitis, a trend exacerbated by rising allergen exposure and environmental pollution. Additionally, the market is bolstered by increased awareness of ocular health and the widespread use of contact lenses. Highlighting the significant demand from the pediatric demographic, the Pediatric Infectious Diseases Society reported in 2024 that infectious conjunctivitis affects approximately one in eight children annually, sustaining substantial market activity.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.87 Billion
Market Size 2031USD 7.94 Billion
CAGR 2026-20315.16%
Fastest Growing SegmentAllergic Conjunctivitis
Largest MarketNorth America

Despite these positive growth indicators, the market confronts a major obstacle due to the expiration of patents for key blockbuster drugs, leading to intensified competition from generic manufacturers. The entry of these lower-cost generic alternatives exerts significant downward pressure on pricing and revenue margins for established pharmaceutical companies, which may potentially hinder investment in novel drug development. Consequently, this competitive environment challenges market expansion by eroding the profitability of branded therapeutics and saturating the sector with commoditized treatment options.

Market Driver

The increasing global prevalence of infectious and allergic conjunctivitis serves as a primary catalyst for the growth of the treatment market, generating consistent demand for a variety of therapeutic interventions. This driver is fueled by frequent seasonal outbreaks and a rising burden of chronic allergic conditions among adult populations. For instance, the Hindustan Times reported that in June 2025, medical facilities in Mumbai observed a sharp 20% to 30% increase in conjunctivitis cases attributed to seasonal viral pathogens, underscoring the rapid transmissibility and acute demand associated with infectious waves. The market's scope is further broadened by non-infectious conditions; a study cited by the National Institutes of Health in July 2025 indicated that allergic rhinoconjunctivitis affects roughly one in eight adults in the UK, demonstrating a vast patient base requiring long-term management beyond the pediatric sector.

Simultaneously, the market is being reshaped by a surge in approvals and launches of novel therapeutic products, offering patients more advanced and accessible treatment choices. Pharmaceutical companies are actively responding to this demand by introducing both innovative formulations and cost-effective generic alternatives to existing drugs. A significant development in this competitive landscape occurred in March 2025 when, according to Barchart, Glenmark Pharmaceuticals received FDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%, thereby expanding access to effective treatments for ocular itching. This continuous influx of approved therapies not only improves patient access but also drives market value by providing tailored solutions for varying severities of conjunctival inflammation.

Market Challenge

The expiration of patents for blockbuster drugs and the subsequent rise of generic competition constitute a formidable barrier to the financial expansion of the global conjunctivitis treatment market. As exclusive rights to proprietary formulations lapse, the market sees an influx of low-cost generic alternatives that force prices down significantly. This transition commoditizes established treatments, causing a sharp decline in revenue for pharmaceutical developers despite consistent or even increasing prescription volumes. The reduced profit margins from these off-patent medications limit the capital available for reinvestment into research and development, thereby slowing the introduction of innovative, higher-value therapeutic solutions that could drive future market valuation.

The disparity between prescription volume and revenue generation clearly illustrates this value erosion. According to the Association for Accessible Medicines, in 2025, generic medicines accounted for 90% of prescriptions filled in the United States but represented only 12% of total drug spending. This data indicates that while patient usage remains high, the monetary value captured by the market is disproportionately low due to the dominance of lower-priced generics. Such a skewed financial landscape hampers overall market growth by replacing high-revenue branded streams with low-margin commodity sales, ultimately discouraging stakeholders from pursuing costly advancements in ocular drug delivery.

Market Trends

The integration of Tele-Ophthalmology for Remote Management is fundamentally transforming patient triage protocols, particularly for contagious viral forms of the condition. By facilitating remote assessment, clinicians can effectively distinguish between allergic and infectious etiologies without physical contact, thereby significantly reducing the risk of transmission within crowded clinic settings. This modality is witnessing substantial uptake as a primary screening tool for ocular surface complaints. As reported by Physicians Weekly in January 2025, in the 'Tele-ophthalmology as an effective triaging tool for acute ophthalmic concerns' article, a retrospective study of over 6,000 patients revealed that 15.5% of all telehealth encounters were specifically for conjunctival disorders, underscoring the high reliance on virtual care for managing acute conjunctivitis.

Concurrently, the adoption of Nanotechnology in Ocular Therapeutics is addressing critical bioavailability challenges associated with conventional eye drops. Novel nanocarriers, such as nanosuspensions, are being engineered to enhance the solubility and tissue penetration of corticosteroids, which are essential for managing severe inflammatory conjunctivitis. These advanced delivery systems ensure rapid therapeutic onset and sustained efficacy compared to traditional formulations. For instance, according to Modern Optometry in February 2025, within the '2024 in Review: FDA Approvals and Product Launches' article, clobetasol propionate ophthalmic suspension 0.05%, a novel aqueous nanosuspension, demonstrated that 80% of patients experienced complete pain relief within four days, highlighting the superior efficacy of nanotechnology-enabled formulations in treating ocular inflammation.

Key Market Players

  • Novartis AG
  • Bausch & Lomb Inc
  • Allergan UnLtd Co
  • Nicox S.A.
  • Alembic Pharmaceuticals Ltd
  • Sanofi SA
  • Pfizer Inc
  • Sirion Therapeutics Inc
  • SANTEN PHARMACEUTICAL CO., LTD.
  • Auven Therapeutics Management LLLP

Report Scope

In this report, the Global Conjunctivitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Conjunctivitis Treatment Market, By Disease Type

  • Allergic Conjunctivitis
  • Bacterial Conjunctivitis
  • Viral Conjunctivitis

Conjunctivitis Treatment Market, By Formulation Type

  • Ointment
  • Drops
  • Drugs

Conjunctivitis Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Conjunctivitis Treatment Market.

Available Customizations:

Global Conjunctivitis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Conjunctivitis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, Viral Conjunctivitis)
    • 5.2.2. By Formulation Type (Ointment, Drops, Drugs)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Conjunctivitis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Formulation Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Conjunctivitis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Formulation Type
    • 6.3.2. Canada Conjunctivitis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Formulation Type
    • 6.3.3. Mexico Conjunctivitis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Formulation Type

7. Europe Conjunctivitis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Formulation Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Conjunctivitis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Formulation Type
    • 7.3.2. France Conjunctivitis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Formulation Type
    • 7.3.3. United Kingdom Conjunctivitis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Formulation Type
    • 7.3.4. Italy Conjunctivitis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Formulation Type
    • 7.3.5. Spain Conjunctivitis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Formulation Type

8. Asia Pacific Conjunctivitis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Formulation Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Conjunctivitis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Formulation Type
    • 8.3.2. India Conjunctivitis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Formulation Type
    • 8.3.3. Japan Conjunctivitis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Formulation Type
    • 8.3.4. South Korea Conjunctivitis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Formulation Type
    • 8.3.5. Australia Conjunctivitis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Formulation Type

9. Middle East & Africa Conjunctivitis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Formulation Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Conjunctivitis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Formulation Type
    • 9.3.2. UAE Conjunctivitis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Formulation Type
    • 9.3.3. South Africa Conjunctivitis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Formulation Type

10. South America Conjunctivitis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Formulation Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Conjunctivitis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Formulation Type
    • 10.3.2. Colombia Conjunctivitis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Formulation Type
    • 10.3.3. Argentina Conjunctivitis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Formulation Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Conjunctivitis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bausch & Lomb Inc
  • 15.3. Allergan UnLtd Co
  • 15.4. Nicox S.A.
  • 15.5. Alembic Pharmaceuticals Ltd
  • 15.6. Sanofi SA
  • 15.7. Pfizer Inc
  • 15.8. Sirion Therapeutics Inc
  • 15.9. SANTEN PHARMACEUTICAL CO., LTD.
  • 15.10. Auven Therapeutics Management LLLP

16. Strategic Recommendations

17. About Us & Disclaimer